BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15389785)

  • 1. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
    Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; McGree ME; Hebbring SJ; Cunningham JM; Anderson SA; Thibodeau SN; Lieber MM; Jacobsen SJ
    Prostate; 2005 Mar; 62(4):380-7. PubMed ID: 15389785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
    Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ
    Prostate; 2006 Mar; 66(4):392-404. PubMed ID: 16302261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
    Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
    J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer].
    Tong M; Xu Z; Ai JK; Yuan YM; Yin Y; Wang JQ; Li HW; Liu JH; Xin DQ; Zhou LQ; Li M; Na YQ
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1493-6. PubMed ID: 15733480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men.
    Mullan RJ; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ; Roberts RO
    Urology; 2006 Feb; 67(2):300-5. PubMed ID: 16461080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
    Schatzl G; Madersbacher S; Gsur A; Preyer M; Haidinger G; Haitel A; Vutuc C; Micksche M; Marberger M
    Prostate; 2002 Jul; 52(2):130-8. PubMed ID: 12111704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
    Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
    J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.
    Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
    J Urol; 1999 Oct; 162(4):1301-6. PubMed ID: 10492184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
    Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
    Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K
    J Androl; 2009; 30(6):703-10. PubMed ID: 19443907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
    van Gils CH; Onland-Moret NC; Roest M; van Noord PA; Peeters PH
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1194-9. PubMed ID: 14652280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer].
    Tong M; Ai JK; Yuan YM; Yin Y; Zhou LQ; Xin DQ; Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1319-21. PubMed ID: 16029630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
    Scorilas A; Bharaj B; Giai M; Diamandis EP
    Br J Cancer; 2001 Mar; 84(6):760-7. PubMed ID: 11259089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of SRD5A2 genotype and pathological characteristics of prostate tumors.
    Jaffe JM; Malkowicz SB; Walker AH; MacBride S; Peschel R; Tomaszewski J; Van Arsdalen K; Wein AJ; Rebbeck TR
    Cancer Res; 2000 Mar; 60(6):1626-30. PubMed ID: 10749132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
    Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
    Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
    Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.